Nanobiotix ( (NBTX) ) has shared an update.
On March 13, 2025, Nanobiotix announced its voting rights and share capital details, revealing 47,426,851 shares outstanding as of February 28, 2025, with theoretical voting rights totaling 49,207,475 and exercisable voting rights at 49,185,357. This disclosure aligns with French financial regulations and reflects the company’s commitment to transparency, potentially impacting shareholder engagement and market perception.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, focusing on innovative, physics-based therapeutic solutions to improve treatment outcomes. Founded in 2003, it is listed on Euronext Paris and Nasdaq, with subsidiaries in Cambridge, Massachusetts. The company holds over 25 patent families across three nanotechnology platforms targeting oncology, bioavailability and biodistribution, and central nervous system disorders.
YTD Price Performance: 13.79%
Average Trading Volume: 21,787
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $153.2M
For an in-depth examination of NBTX stock, go to TipRanks’ Stock Analysis page.